VEGFR inhibitors as anti-angiogenic agents are widely used as a target-specific treatment option for the management of hepatoma and of other cancer diseases such as renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) [38]. This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.